Syn-Coll
- Category
- Skin & Cosmetic
- Administration routes
- Topical
- Regulatory status
- Cosmetic ingredient
What it is
A synthetic peptide applied to skin, marketed for firmness and fine-line reduction by signaling skin cells into collagen-production mode. Human evidence is thin, limited to small trials of modest wrinkle improvement, while deeper collagen claims rest mainly on lab reasoning. Safety data is limited, reported issues mild (dryness, occasional sensitivity). Not an approved drug in the US; it is sold as a cosmetic ingredient, subject to applicable cosmetic safety and labeling requirements.
Read Full recordStudied uses & evidence
Studied uses(6)
Stimulation of type I and type III collagen synthesis via TGF-beta activation
SpeculativeNo independent study confirms TGF-beta activation; evidence is supplier in-vitro data only.
Reduction of facial wrinkles (depth, area, and roughness)
LowTwo small open-label human studies report wrinkle reduction, but neither isolates this peptide alone.
Improved skin firmness, elasticity, and pore appearance
SpeculativeFirmness and density gains reported in combination-product studies; pore effects were not studied.
Evidence limits
- Evidence Level
- Moderate
Clinical evidence for Syn-Coll is moderate and primarily manufacturer-sponsored. The strongest clinical data comes from DSM/Firmenich's 84-day study with 60 volunteers demonstrating dose-dependent wrinkle reduction (7-12%) measured by PRIMOS surface topography, with Syn-Coll outperforming both placebo (3.5x) and palmitoyl pentapeptide-3. A separate 33-person study showed subjective improvements in firmness (77%) and pore appearance (60%) at 4 weeks. In vitro evidence for TGF-beta activation and 2-3 fold collagen increases is consistent and well-characterized. A 2020 nanoliposome delivery study with 15 women provided additional human evidence showing wrinkle volume reduction (25%) and elasticity improvement (36.6%) when Syn-Coll was combined with carnosine and Argireline. However, as noted by Resende et al. 2021 (PMID 34451799), neither efficacy studies for the use of palmitoyl tripeptide-5 alone nor in sensitive skin applications meeting rigorous independent clinical trial standards are available. The cited CIR review does not establish a final safety conclusion for palmitoyl tripeptide-5.
Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Cautions & risk summary
General cautions
Pregnancy or breastfeeding
AbsoluteNo human reproductive safety data exists for this peptide. Effects on fetal development are unknown.
Children under 18
AbsoluteNo pediatric safety data. Not recommended for use in minors.
Known hypersensitivity
AbsoluteDiscontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).
Risk summary(4)
Risks = level of concern: High · Moderate · Low · Theoretical
Mild skin dryness or flaking
LowAllergic or sensitivity reaction (rare)
LowTheoretical TGF-beta pathway concerns
TheoreticalLimited long-term safety data
Moderate
Further reading
- Overview in Full record
- Safety & interactions in Full record
- Research & benefits in Full record
- Regulation & availability in Full record
- Sources in Full record
- Frequently asked questions in Full record
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.